Generic Name and Formulations:
Imipramine pamoate (equal to HCl) 75mg, 100mg, 125mg, 150mg; caps.
- Online Module Seeks to Educate Nurses on the Identification and Management of Hypersensitivity Reactions to Chemotherapy
- Nursing and Patient Education on Immunotherapy-related Adverse Events
- Internalizing, Externalizing Behavioral Problems a Significant Postdiagnosis Concern in Children With Cancer
Indications for TOFRANIL-PM:
Outpatients: initially 75mg/day; max 200mg/day. Inpatients: initially 100–150mg/day, max 300mg/day. Adolescents or elderly: start with Tofranil 25–50mg/day; usual max 100mg/day. For maintenance doses >75mg, may substitute Tofranil-PM for divided or bedtime dosing.
During or within 14 days of MAOIs. Concomitant linezolid or IV methylene blue. Acute post-MI.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults; monitor for clinical worsening or unusual changes. Monitor for emergence of serotonin syndrome; discontinue if occurs. Screen for bipolar disorder. Cardiovascular disease. Increased intraocular pressure. Urinary retention. Hyperthyroidism. Seizure disorder. Angle-closure glaucoma. Mania/hypomania. Psychosis. ECT. Diabetes. Renal or hepatic impairment. Perform leukocyte and blood counts if fever and sore throat develops. Discontinue prior to surgery or evidence of pathological neutrophil depression. Write ℞ for smallest amount feasible. Elderly. Pregnancy. Nursing mothers: not recommended.
See Contraindications. Increased risk of serotonin syndrome with other serotonergic drugs (eg, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's Wort) or with drugs that impair serotonin metabolism (eg, MAOIs, linezolid, IV methylene blue). Potentiates alcohol, sympathomimetics (eg, epinephrine, norepinephrine), CNS depressants. Potentiated by methylphenidate, CYP2D6 inhibitors; monitor plasma levels with cimetidine, fluoxetine, quinidine, SSRIs, phenothiazines, type 1C antiarrhythmics (eg, propafenone, flecainide). Antagonized by barbiturates, phenytoin. Paralytic ileus with anticholinergics. Blocks guanethidine, clonidine. Possible cardiotoxicity with concomitant thyroid medications.
Drowsiness, anticholinergic effects, CNS overstimulation, arrhythmias, extrapyramidal symptoms, hypo- or hypertension, nausea, fatigue, rash, increased perspiration, headache, changes in blood sugar, photosensitivity, edema, blood dyscrasias (discontinue if occurs), jaundice.
Tabs—30, 100; Caps—30
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|